NEWS & EVENTS
CATCH UP WITH OUR LATEST NEWS
March 12, 2024
Capsida Biotherapeutics Announces Promotion of Rob Murphy to Chief Manufacturing and Quality Officer
Promotion reinforces commitment to advancing our wholly owned gene therapy pipeline…
February 21, 2024
Capsida Biotherapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference
THOUSAND OAKS, Calif., February 21, 2024 -- Capsida Biotherapeutics (“Capsida”)…
October 3, 2023
Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies
Strategic partnership leverages Capsida’s next-generation manufacturing…
September 20, 2023
Capsida Biotherapeutics to Present at Jefferies Cell & Genetic Medicine Summit and the 2023 Cell & Gene Meeting on the Mesa
THOUSAND OAKS, Calif., September 20, 2023 -- Capsida Biotherapeutics (“Capsida”)…
July 11, 2023
Capsida Biotherapeutics Announces Publication in Nature Nanotechnology Identifying Novel Capsid With Significantly Increased Brain Transduction
Foundational research by Capsida and Caltech demonstrates ability to engineer AAVs…
June 2, 2023
Capsida Biotherapeutics to Present New Preclinical Data on Potential of Systemically Delivered Next-Generation AAV Therapeutics for Treatment of Genetic Epilepsy
Preclinical data show IV administration of a next-generation gene therapy produced…
May 10, 2023
Capsida Biotherapeutics to Present New Data Showing Increased Capsid Expression in CNS at American Society of Gene & Cell Therapy 26th Annual Meeting
Preliminary data show next-generation engineered capsids in non-human primates…
March 7, 2023
Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer
Industry veteran added to complement co-founders Nicholas Flytzanis, Ph.D. and Nick…
February 23, 2023
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
Partnership Combines AbbVie's extensive capabilities with Capsida's novel…
January 18, 2023
Capsida Biotherapeutics Announces Appointment of Julie Hakim as Chief Financial Officer
Hakim brings more than 25 years’ experience leading finance and exponential growth…
January 4, 2023
Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases
THOUSAND OAKS, Calif. January 4, 2023 – Capsida Biotherapeutics Inc. (“Capsida”)…
May 18, 2022
Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Platform utilizes combinatorial engineering and automation to screen in…
May 17, 2022
Capsida Biotherapeutics Presents New Data Validating Potential of Its Targeted, Non-invasive Gene Therapy Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Preclinical results demonstrate proof-of-concept of early generation AAV-engineered…
April 19, 2022
Capsida Co-Founders Named to Endpoints’ Top 20 Scientists Under 40
Dr. Nick Goeden and Dr. Nick Flytzanis – “the Nicks,” as many of their colleagues…
March 22, 2022
Capsida Biotherapeutics Announces Appointment of Rayne Waller to Chief Operating Officer
Company creates chief operating officer role and appoints veteran manufacturing and…
February 3, 2022
PharmaVoice profiles Capsida CEO Peter Anastasiou
Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality…
December 9, 2021
Capsida Biotherapeutics Announces Publication in Nature Neuroscience From Caltech Demonstrating Robust, Non-invasive IV Gene Delivery Targeted to the Brain While Avoiding Liver
THOUSAND OAKS, Calif., December 9, 2021 -- Capsida Biotherapeutics, Inc., an…
December 7, 2021
Capsida Biotherapeutics Poised to Capitalize on Industry-leading Gene Therapy Technology With New CEO, CSO, and CTO
Longtime industry executive Peter Anastasiou appointed Chief Executive Officer…
December 2, 2021
Capsida Technology and Clinical Leadership to Present at Gene Therapy for Neurological Disorders Conference
Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a…
July 22, 2021
Capsida Biotherapeutics Unveils Next-Generation Gene Therapy Manufacturing
New 15,000 square-foot facility in Thousand Oaks will enable industry leading…
June 15, 2021
CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia
Collaboration leverages expertise and capabilities of both companies towards…
May 12, 2021
Capsida Appoints Swati Tole, M.D., as Chief Medical Officer
Clinical development leader will help advance Capsida’s breakthrough AAV gene…
April 29, 2021
Capsida Biotherapeutics Debuts with $140 Million of Capital
Versant, Westlake Village BioPartners launch next-generation gene therapy company…
EVENTS
Posters Presented at the ASGCT Annual Meeting
Los Angeles, California
May 2023
Sophia Petraki, Leandro Fernandez, Amit Mirchandani, Abagail Wells, Hari Acharya, Heidy Morales, Elissa Troisi, Jesse Granados, Emily Springfield
Exploring upstream process conditions to improve productivity for novel AAV Capsids
Heidy Morales, Elissa Troisi, Lysa-Anne Volpe, Erick Reyes-Ramirez, Garrett Garrido, Jenna Rodden, Jesse Granados, Hari Acharya
Jesse Granados, Francesca Sanchez, Izamary Marquez, David Chu